Skip to main content
. Author manuscript; available in PMC: 2018 Jan 28.
Published in final edited form as: J Diabetes Complications. 2016 Oct 7;31(2):449–455. doi: 10.1016/j.jdiacomp.2016.10.003

Table 3.

Echocardiography measurements at rest at baseline and three months

Placebo (n = 12) Exenatide (n = 11)
Baseline 3 Month Baseline 3 Month
Circumferential Strain −23.5 ± 0.7 −22.6 ± 1.4 −23.7 ± 1.7 −25.6 ± 1.78
Longitudinal Strain −19.3 ± 0.7 −18.3 ± 0.8 −17.6 ± 1.2 −18.5 ± 1.2
Stroke Volume (mL/beat) 81.0 ± 12.8 80.7 ± 1.9 88.2 ± 3.3 93.3 ± 2.8
MV E Wave Velocity 0.74 ± 0.06 0.78 ± 0.06 0.69 ± 0.04† 0.61 ± 0.06†
MV E:A Wave Velocity 0.83 ± 0.06 0.82 ± 0.06 1.04 ± 0.13 0.85 ± 0.09
MV Deceleration Time 283.3 ± 12.8 239.8 ± 14.6 236.0 ± 6.6 234.6 ± 17.0
Septal E’ 0.07 ± 0.01 0.07 ± 0.1 0.08 ± 0.01 0.08 ± 0.01
Septal E:E’ 10.4 ± 0.8 12.6 ± 1.4 9.6 ± 0.7 8.3 ± 0.9*
Lateral E’ 0.09 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 0.09 ± 0.01
Lateral E:E’ 7.6 ± 1.0 8.4 ± 1.2 8.1 ± 0.7 6.7 ± 0.6*

Data are Mean ± Standard Error. Mitral Valve: MV.

†

P < 0.05 Different compared with placebo at same time point.

*

P < 0.05 Different compared with baseline within group.

†

P < 0.05 Main effect of drug.